High mobility group A: a novel biomarker and therapeutic target in pancreatic adenocarcinoma.
High mobility group A1 (HMGA1) proteins are architectural transcriptional factors that are over-expressed in a wide range of human malignancies. Recently published evidence suggests HMGA1 is a promising candidate biomarker and therapeutic target in pancreatic cancer. This review summarises data implicating HMGA1 as an important mediator of progression in human cancer and in pancreatic cancer.
Liau
S S
SS
Department of Surgery, Addenbrooke's Hospital, Cambridge. liauss@doctors.org.uk
Whang
E
E
D000230:Adenocarcinoma / Q000235:genetics* / Q000628:therapy; D014408:Biomarkers, Tumor / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic; D005838:Genotype; D025741:HMGA1a Protein / Q000235:genetics*; D006801:Humans; D010190:Pancreatic Neoplasms / Q000235:genetics* / Q000628:therapy; D010641:Phenotype
D014408:Biomarkers, Tumor; D025741:HMGA1a Protein